We examined whether chronic systemic treatment with agonists for peroxisome proliferator-activated receptor ␣ (PPAR␣) influences neuroinflammation induced by lipopolysaccharide (LPS) injection into the somatosensory cortex in adult mice. Mice were pretreated with Wy-14643 or fenofibrate, both at 30 mg/kg, for 7 days. These treatment protocols increased the amount of PPAR␣ mRNA and active form of PPAR␣ protein in the brain. LPS injection reduced the PPAR␣ mRNA level in the brain. On the contrary, TNF␣, IL-1␤, IL-6, iNOS, COX-2, ICAM-1, VCAM-1, and PECAM-1 were elevated at 6 h after LPS. Wy-14643 and fenofibrate inhibited the elevations of TNF␣, IL-1␤, IL-6, COX-2, ICAM-1, and VCAM-1. Wy-14643, but not fenofibrate, also attenuated the iNOS elevation. At 3 days after LPS, Wy-14643 and fenofibrate showed similar inhibitions in these molecules. LPS injection also elevated IL-6 protein levels in the brain and serum at 6 h, which was inhibited by fenofibrate. Histological analyses showed that Wy-14643 and fenofibrate profoundly attenuated microglia/macrophage activation, neutrophil recruitment, and neuronal injury at 3 days after LPS. These findings suggest that activation of PPAR␣ attenuates neuroinflammation in the adult mouse brain, implicating that PPAR␣ may be a potential therapeutic target for CNS diseases in which neuroinflammation plays a substantial role.
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Introduction
Peroxisome proliferator-activated receptor (PPAR) is a liganddependent transcription factor (Chinetti et al., 2000) . Currently, three subtypes ␣, ␥, and ␤/␦ are identified. PPARs regulate lipid/glucose metabolism and adipocyte differentiation; therefore, PPARs have gained a great deal of attention as a potential therapeutic target for metabolic syndrome (Kersten et al., 2000) .
PPAR␣ has been implicated in inflammation (Cunard et al., 2002; Staels et al., 1998) . PPAR␣ null mice showed a prolonged inflammation in response to leukotriene B4 (Devchand et al., 1996) . PPAR␣ agonists exert anti-inflammatory actions in a variety of inflammatory diseases (Okamoto et al., 2005; Tanaka et al., 2001) , including CNS diseases (reviewed in Drew et al., 2006; Heneka and Landreth, 2007; Bright et al., 2008) . For instance, gemfibrozil and fenofibrate improved neurological signs in a mouse model of multiple sclerosis (Lovett-Racke et al., 2004) . These effects of PPAR␣ agonists required PPAR␣ expression (Gocke et al., 2009) .
PPAR␣ activation has been shown to suppress glial inflammatory responses to lipopolysaccharide (LPS), an endotoxin which is expressed on the outer membrane of bacteria. LPS-induced innate immune response in the brain is mediated through Toll-like receptor 4 (Rivest, 2009). In vitro studies using dissociated glial cultures have provided a substantial amount of data concerning the effects of PPAR␣ activation on the glial response to LPS (Lee et al., 2005; Paintlia et al., 2008a,b; Xu et al., 2005 Xu et al., , 2006 Xu et al., , 2007 ; however, in vitro studies often lack other crucial cellular components, such as endothelial cells and peripheral blood cells, for inflammation. One study recently reported that maternal LPS exposure depleted developing oligodendrocyte in the fetal brain, which was prevented by Wy-14643, a PPAR␣-specific agonist (Paintlia et al., 2008b) . Less is known about the in vivo effects of PPAR␣ activation on LPS-induced neuroinflammation in adult brain.
Gemfibrozil and fenofibrate are prescribed for dyslipidemia. Most of dyslipidemic cases are seen in adults. In addition, little is known about the effects of chronic treatment with PPAR␣ agonists on neuroinflammation. Therefore, we examined the influence of chronic treatment with PPAR␣ agonists on neuroinflammation in adult mice. In the current study, we induced neuroinflammation by injecting LPS directly into the somatosensory cortex so that potential direct interactions between the systemically administered PPAR␣ agonists and LPS were minimized. This model could also minimize the potential influence of LPS on peripheral organs.
